Junior Phocéenne Du Médicament (Jpm) company information, Employees & Contact Information

Biopharma, Medtech Deal Reports for Q3 2025 J.P. Morgan

Friday Five – JPM preview, GSK gets a GIST, J&J guns for Tagrisso…and more FirstWord Pharma

JPM25: Deals, Summit’s bravado and gene therapy headwinds BioPharma Dive

Another ‘JPM Week’ nears: Here’s my roadmap for biotech’s annual SF gathering statnews.com

JPMorgan's top biotech and pharma picks for the second half CNBC

J.P. Morgan Notebook: New Launches Are Delivering Big For Big Pharma Citeline News & Insights

JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave' Fierce Pharma

Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation MedCity News

Previewing JP Morgan 2025 — the key trends to watch in biopharma for the year ahead FirstWord Pharma

EY Predicts Smarter, Smaller M&A in Biotech and Pharma for 2025 geneonline.com

With a major patent cliff coming, will JPM play host to some serious deal-making? statnews.com

JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B Fierce Pharma

Vertex leads J.P. Morgan's top biotech picks list for 2025 (NASDAQ:VRTX) Seeking Alpha

Healthcare-pharma and AI-focused partnerships stand out at JP Morgan Healthcare Conference eMarketer

2 Pharma stocks to buy now for an upside of up to 42%; Recommended by JP Morgan Trade Brains

'Own JP Morgan, don't let JP Morgan own you': Biopharma—and Jill Biden—show up for JPM25 Fierce Biotech

Healthcare Conference J.P. Morgan

After a 'reset' year for M&A, expect bigger deals in 2025: reports Fierce Pharma

Life Science & Biotech: Banking & Financial Investments J.P. Morgan

JPM25, Day 3: AbbVie's 'clear runway to growth' allows it to focus on early-stage acquisitions Fierce Pharma

Burning questions for the 2024 JPM Healthcare Conference statnews.com

JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says Fierce Pharma

Key takeaways from the JP Morgan Healthcare Conference FirstWord Pharma

2025 J.P. Morgan Week pharmaphorum

CEOs Head to JPMorgan Pharma Event With M&A Hopes, High Security Bloomberg.com

Today at JP Morgan: J&J delivers a bigger M&A deal, industry largely tight-lipped on Trump but regulators share concerns…and more FirstWord Pharma

Rivus Pharmaceuticals to Present Corporate Update at 2025 J.P. Morgan Healthcare Conference PR Newswire

By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years Pharma Voice

JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline Clinical Trials Arena

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting BioPharma Dive

JPM 2022: Fosun Pharma invests in Insilico Medicine for its AI drug discovery programs Fierce Biotech

JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout Fierce Pharma

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales Fierce Pharma

JPM: New Novartis pharma chief rethinks its drug-launch formula Fierce Pharma

Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma Fierce Biotech

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B Fierce Pharma

Zealand Pharma Gains as JPMorgan Flags $10 Billion Opportunity Bloomberg.com

JPM 2022: Sanofi has designs on creating Big Pharma's 'strongest' immunology franchise, CFO says Fierce Pharma

JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch Fierce Pharma

JPM: 'Stick a fork in it'—J.P. Morgan in San Francisco is done, reader poll results say Fierce Pharma

JPM, Day 1: Moderna's 'inflection year,' Gilead's Veklury boost, Genentech's 'silver linings' Fierce Pharma

JPM: Alexion gives an updated look at what AstraZeneca's getting for $39B Fierce Pharma

JPM 2022: Amgen dials up biosimilar ambitions, with at least $4B in expected sales by 2030 Fierce Pharma

Senior Pharma and Biotech Leaders to Gather the Weekend Immediately Prior to JP Morgan Healthcare Conference for 2 Day Networking Forum, San Francisco CEO, Hosted by Longwood Healthcare Leaders Newswire.com

JPM 2024: Taiwan's Pharma Giant Bora Pharmaceuticals Climbing US Pharmaceutical Summit geneonline.com

JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says Fierce Pharma

JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals Fierce Pharma

JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B-plus Fierce Pharma

JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works Fierce Biotech

JPM: Viatris CEO trumpets 'disciplined' deal-making for postmerger road map Fierce Pharma

JPM: Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce Fierce Pharma

Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan Fierce Pharma

JPM: Jazz eyes a 'dramatic' shift to new-drug revenue by 2022, CEO says Fierce Pharma

JPM24: Roche says rebound in hematology sparked by potential of newly approved Lunsumio, Columvi Fierce Pharma

JPM 2019: Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal Fierce Pharma

Teva Pharma stock rating reiterated by JPMorgan ahead of Q2 earnings Investing.com

JPM: 'Very soon,' says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data Fierce Pharma

JPM25: Regeneron CEO says it needs more 'arrows in its quiver' as Eylea HD sales fall short Fierce Pharma

Pfizer CEO talks up experimental oral GLP-1 diabetes/obesity hopeful as $90B Lilly, Novo battle looms Fierce Pharma

JPM: A Humira-beating $20B in sales from Skyrizi and Rinvoq? It's possible, AbbVie CEO says Fierce Pharma

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU Fierce Pharma

JPM: Glaxo's cancer unit, in commercial 'building mode,' gets choosy with M&A Fierce Pharma

JPM: How will Amgen make its $13.4B Otezla buy pay off? New launches, for one, CEO says Fierce Pharma

Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout Fierce Pharma

LifeSci Bosses Apologize for Scantily Clad Women at J.P. Morgan Party After Pharma Execs Issue Letter BioSpace

JP Morgan upgrades Torrent Pharma to 'Overweight', lifts target; stk up 5% Business Standard

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy? The Motley Fool Australia